<DOC>
	<DOCNO>NCT01597258</DOCNO>
	<brief_summary>The objective surveillance collect information 1 ) adverse drug reaction expect LPD ( unknown adverse drug reaction ) , 2 ) incidence adverse drug reaction surveillance , 3 ) factor consider affect safety and/or efficacy drug .</brief_summary>
	<brief_title>Safety And Efficacy Of Crizotinib ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>All patient investigator prescribes Crizotinib ( XALKORI ) register .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>All patient investigator prescribes XALKORI . ( Patients need administer Crizotinib ( XALKORI ) order enrol case surveillance . ) Patients administer XALKORI spite enrol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>All case surveillance Japan</keyword>
	<keyword>ALK-positive unresectable advanced and/or recurrent non-small cell lung cancer</keyword>
</DOC>